QuickView: Nearing transition to a commercial story
Aeterna Zentaris is poised to transition to a commercial entity in 2015. Macrilen has an FDA PDUFA date of 5 November in the evaluation of adult growth hormone deficiency (AGHD), a category currently dominated by insulin tolerance tests. Aeterna plans to launch Macrilen in January 2015, if approved. With $39m in cash at 30 June 2014, Aeterna is funded through the reporting of key interim data from its Phase III study of zoptarelin doxorubicin for advanced endometrial cancer, expected near mid-2015.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.